Stephen Divers, MD
Hematology & Oncology · Hot Springs, ARNPI 1760469407
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.3%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Daiichi Sankyo Inc. at 27.1% of the total. Among hematology & oncology clinicians in AR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,047 payments — averaging $52.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$15K
- Pharmacosmos Therapeutics Inc.$11K
- AstraZeneca$7K
- Janssen Scientific Affairs, LLC$2K
- Amgen$2K
- Johnson & Johnson$1K
- plus $17K from 54 others
Across 74 payments — averaging $7532.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$192K
- Astrazeneca UK Limited$166K
- Genentech, Inc.$91K
- Eli Lilly$86K
- Bristol Myers Squibb$22K
- Spectrum Pharmaceuticals Inc.$562
What the payments were for
- Consulting fees$27,26149%
- Speaking & faculty fees$7,39213%
- Travel & lodging$1,6393%
- Food & beverage$18,84234%
- Education$1680%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$55,301 in reported general payments places this provider in the 90th percentile of 92 hematology & oncology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabliviCaplacizumab-Yhdp | 12 | $2,946,374 |
| RevlimidLenalidomide | 95 | $1,684,866 |
| JakafiRuxolitinib Phosphate | 65 | $980,454 |
| BrukinsaZanubrutinib | 30 | $446,633 |
| CabometyxCabozantinib S-Malate | 17 | $418,972 |
| TagrissoOsimertinib Mesylate | 20 | $303,028 |
| NubeqaDarolutamide | 24 | $245,930 |
| KisqaliRibociclib Succinate | 15 | $217,488 |
| ErleadaApalutamide | 11 | $166,593 |
| Lupron DepotLeuprolide Acetate | 20 | $154,883 |
| VenclextaVenetoclax | 14 | $144,109 |
| Somatuline DepotLanreotide Acetate | 12 | $115,327 |
| Abiraterone Acetate | 40 | $86,654 |
| EliquisApixaban | 98 | $85,914 |
| TrazimeraTrastuzumab-Qyyp | 14 | $71,308 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SanofiCablivi | $442 | $2,946,37412 claims |
| Bristol Myers SquibbRevlimid | $600 | $1,684,86695 claims |
| Incyte CorporationJakafi | $465 | $980,45465 claims |
| Beigene USA, Inc.Brukinsa | $1,145 | $446,63330 claims |
| Exelixis Inc.Cabometyx | $314 | $418,97217 claims |
| AstraZenecaTagrisso | $6,526 | $303,02820 claims |
| AbbVieLupron Depot, Venclexta | $469 | $298,99234 claims |
| BayerNubeqa | $345 | $245,93024 claims |
| NovartisKisqali | $1,252 | $217,48815 claims |
| Johnson & JohnsonErleada, Xarelto | $1,479 | $212,51964 claims |
| PfizerEliquis, Trazimera, Retacrit | $901 | $176,561123 claims |
| Ipsen Biopharmaceuticals, IncSomatuline Depot | $104 | $115,32712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 92 hematology & oncology providers in Arkansas.
Other hematology & oncology in Hot Springs
- Lingyi ChenHot Springs$20K
- Robert MuldoonHot Springs$17K
- Roy WebbHot Springs$14K
- Amy ClevelandHot Springs$9K
- Manjusha KotaHot Springs$6K
- Eric SchaeferFayetteville$466K
- Frits van RheeLittle Rock$218K
- Isam Abdel-KarimFort Smith$199K
- Appalanaidu SasapuLittle Rock$63K
- Stephan RosenfeldFayetteville$61K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.